| Amy Andersen, MD | |
|
1765 Lininger Ln, North Liberty, IA 52317-2316 | |
| (319) 665-3055 | |
| Not Available |
| Full Name | Amy Andersen |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 25 Years |
| Location | 1765 Lininger Ln, North Liberty, Iowa |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932169778 | NPI | - | NPPES |
| 2192823 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 33637 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Medical Center - Cedar Rapids | Cedar rapids, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Physician Associates Inc | 1355242496 | 91 |
| On With Life Inc | 4385553965 | 126 |
News Archive
Beatriz Apellaniz, PhD holder of the UPV/EHU-University of the Basque Country, has studied in her PhD thesis HIV regions that could be used to design a vaccine. The researcher has focussed her research on a specific region of the surface protein of the Human Immunodeficiency Virus (HIV), which is responsible for the Autoimmune Deficiency Syndrome (AIDS), one of the diseases with the greatest human morbidity and mortality.
On Wednesday, March 10 and Thursday, March 11, the FDA is convening an Advisory Committee meeting on the clinical trial design for long acting beta-2 adrenergic agonists.
Men who develop prostate cancer, especially the more aggressive and dangerous forms that spread throughout the body, tend to retain denser bones as they age than men who stay free of the disease, suggests new research from Johns Hopkins and the National Institute on Aging (NIA), part of the National Institutes of Health.
Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that it has earned $4 million in milestone payments upon the initiation of two Phase 1 clinical trials of IPI-145.
› Verified 2 days ago
| Entity Name | Mercy Physician Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427254952 PECOS PAC ID: 1355242496 Enrollment ID: O20040120000805 |
News Archive
Beatriz Apellaniz, PhD holder of the UPV/EHU-University of the Basque Country, has studied in her PhD thesis HIV regions that could be used to design a vaccine. The researcher has focussed her research on a specific region of the surface protein of the Human Immunodeficiency Virus (HIV), which is responsible for the Autoimmune Deficiency Syndrome (AIDS), one of the diseases with the greatest human morbidity and mortality.
On Wednesday, March 10 and Thursday, March 11, the FDA is convening an Advisory Committee meeting on the clinical trial design for long acting beta-2 adrenergic agonists.
Men who develop prostate cancer, especially the more aggressive and dangerous forms that spread throughout the body, tend to retain denser bones as they age than men who stay free of the disease, suggests new research from Johns Hopkins and the National Institute on Aging (NIA), part of the National Institutes of Health.
Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that it has earned $4 million in milestone payments upon the initiation of two Phase 1 clinical trials of IPI-145.
› Verified 2 days ago
| Entity Name | Mercycare Management, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467659268 PECOS PAC ID: 2466343363 Enrollment ID: O20040322000692 |
News Archive
Beatriz Apellaniz, PhD holder of the UPV/EHU-University of the Basque Country, has studied in her PhD thesis HIV regions that could be used to design a vaccine. The researcher has focussed her research on a specific region of the surface protein of the Human Immunodeficiency Virus (HIV), which is responsible for the Autoimmune Deficiency Syndrome (AIDS), one of the diseases with the greatest human morbidity and mortality.
On Wednesday, March 10 and Thursday, March 11, the FDA is convening an Advisory Committee meeting on the clinical trial design for long acting beta-2 adrenergic agonists.
Men who develop prostate cancer, especially the more aggressive and dangerous forms that spread throughout the body, tend to retain denser bones as they age than men who stay free of the disease, suggests new research from Johns Hopkins and the National Institute on Aging (NIA), part of the National Institutes of Health.
Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that it has earned $4 million in milestone payments upon the initiation of two Phase 1 clinical trials of IPI-145.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amy Andersen, MD Po Box 1824, Cedar Rapids, IA 52406-1824 Ph: (319) 369-4505 | Amy Andersen, MD 1765 Lininger Ln, North Liberty, IA 52317-2316 Ph: (319) 665-3055 |
News Archive
Beatriz Apellaniz, PhD holder of the UPV/EHU-University of the Basque Country, has studied in her PhD thesis HIV regions that could be used to design a vaccine. The researcher has focussed her research on a specific region of the surface protein of the Human Immunodeficiency Virus (HIV), which is responsible for the Autoimmune Deficiency Syndrome (AIDS), one of the diseases with the greatest human morbidity and mortality.
On Wednesday, March 10 and Thursday, March 11, the FDA is convening an Advisory Committee meeting on the clinical trial design for long acting beta-2 adrenergic agonists.
Men who develop prostate cancer, especially the more aggressive and dangerous forms that spread throughout the body, tend to retain denser bones as they age than men who stay free of the disease, suggests new research from Johns Hopkins and the National Institute on Aging (NIA), part of the National Institutes of Health.
Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that it has earned $4 million in milestone payments upon the initiation of two Phase 1 clinical trials of IPI-145.
› Verified 2 days ago
Dr. Kenneth Andrew Hubel, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2562 Oak Cir Ne, North Liberty, IA 52317 Phone: 319-626-6562 | |
Stacie Ann Kasper, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1765 Lininger Ln, North Liberty, IA 52317 Phone: 319-467-7888 Fax: 319-467-7889 | |
Lisa R Johnson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 420 Community Dr Ste 1, North Liberty, IA 52317 Phone: 319-626-6006 | |
Natalie L Hempy, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 585 W Cherry St, North Liberty, IA 52317 Phone: 319-626-6006 Fax: 319-626-3400 | |
Sarah Von Harz, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 420 Community Dr Ste 1, North Liberty, IA 52317 Phone: 319-626-6006 | |
Jason Powers, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3 Lions Dr, North Liberty, IA 52317 Phone: 319-626-5680 Fax: 319-626-5687 | |
Cheryl K Johnson, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 585 W Cherry St, North Liberty, IA 52317 Phone: 319-626-6006 Fax: 319-626-3400 |